"VIVA 2019: IN.PACT AV DCB Shows “Consistent Effectiveness Performance” In Subgroup Analysis"
Medtronic shared a six-month subgroup analysis from the IN.PACT AV Access trial, which evaluated how the IN.PACT AV DCB—an investigational device not currently approved for use in the USA—performed in different target lesion types, arteriovenous fistula (AVF) types, and target lesion locations in the arm with the goal of determining where the DCB may demonstrate the most clinical benefit to patients receiving haemodialysis. According to Robert Lookstein, MD, professor of diagnostic, molecular and interventional radiology and surgery at the Icahn School of Medicine at Mount Sinai, “The analysis assessed the six-month target lesion primary patency (TLPP) in participants with de novo and restenotic lesions in comparison between the treatment of IN.PACT AV DCB and standard PTA control.”
— Robert A. Lookstein, MD, MHCDL, FSIR, FAHA, FSVM, Professor, Diagnostic, Molecular and Interventional Radiology, Surgery, Icahn School of Medicine at Mount Sinai